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Abstract: We report a case of an acute endothelial failure after the implantation of a new 
cosmetic, colored, artificial iris diaphragm implant called NewIris®. A 21-year-old woman 
came to us complaining of progressive loss of vision and pain after NewIris lenses had been 
implanted. Decreased visual acuity, corneal edema, and increased intraocular pressure in both 
eyes appeared only 3 weeks after the surgery. The lenses were removed as soon as possible but 
had already severely affected the endothelial cell count. NewIris implants are an alternative to 
cosmetic contact lenses, but they are not as safe as other phakic anterior chamber intraocular 
lenses, nor are they a good option for the patient.
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Introduction
Cosmetic, colored contact lenses are worn to give the appearance of a different eye 
color. A new artificial iris diaphragm implant was first presented by Khan in 2004.1 
This device was designed to improve the appearance of patients with partial coloboma, 
traumatic iridectomy, or ocular albinism. However this implant has also been promoted 
on the Internet as a cosmetic implant for consumers who wish to change the color of 
their eyes
We report a severe case of corneal decompensation 3 weeks after the implantation 
of NewIris® lenses (Kahn Medical Devices Corp, Panama City, Panama) which have 
resulted in lasting visual impairment despite their removal.
Case report
A 21-year-old woman came to the emergency department complaining of progressive 
loss of vision and pain in both eyes. She had had ocular surgery to change her eye 
color 3 weeks before in Panama. The patient’s best corrected visual acuity (BCVA) 
was 20/60 in the right eye (OD) and 20/80 in the left (OS). Slit lamp examination 
showed significant results of anterior chamber blue-colored implants with angle-
support (NewIris implants) (Figure 1A): corneal edema, pigmented precipitates, 
and flare grade 1 in both eyes. Intraocular pressure (IOP) with Goldman applanation 
tonometry was 30 mmHg in OD and 35 mmHg in OS. The endothelial cell count was 
1071 cells/mm2 in OD and 950 cells/mm2 in OS, with some changes in the size and 
shape of the cells (Figure 2).
Anterior segment optical coherence tomography (OCT) revealed areas of implant–
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Topical dexamethasone 0.1%, timolol 0.05%, and dorzo-
lamide treatment was initiated and continued until surgery. 
The lenses were removed through a scleral incision. This was 
achieved by corneal paracentesis and the injection of dispersive 
viscoelastic to protect the endothelium. Then we performed 
a large scleral wound (about 10 mm) 3 mm from the corneo-
scleral limbus. The implant was folded and removed en bloc. 
Scleral suture with nylon 10/0 was performed to close the 
wound following anterior chamber washout of the viscoelastic. 
Once the lenses had been removed we realized that no preven-
tive iridotomies had been made before surgery.
Postoperative treatment consisted of topical dexametha-
sone 0.1% and tobramycin 0.3% combination drops 4 times 
a day during the first week, then decreasing to 1 drop per 
week for 4 weeks of treatment. Timolol 0.05% twice a day 
was added during the first week.
There were no postoperative recovery complications and 
at 4 weeks after surgery the BCVA was 20/20 in the OD and 
20/25 in the OS. Corneal edema had completely resolved 
in both eyes but some pigment had been deposited in the 
corneal endothelium. IOP was controlled without treatment 
and the endothelial cell count maintained as before the lenses 
were removed.
Today, 2 years after NewIris removal, visual acuity is 
maintained at 20/20 in both eyes and IOP is normalized 
  without any treatment. Despite this, severe losses of endothe-
lial cell count and pigmented precipitates remain.
Discussion
The NewIris lens (Figure 1B) is made of very thin ophthalmic-
grade silicone, colored and elastic, so that it can be inserted 
through a 2.8 mm clear corneal incision. The device has a 
diameter of 15 mm with a central opening in the pupil of 
3.5 mm and 0.16 mm thickness.1 The NewIris features flaps 
instead of haptics, by which it can be placed without any 
supposed pressure on the angle. It is available in 3 colors 
intended to mimic the natural iris. A similar artificial iris 
diaphragm implant has been used on patients with anatomic 
or functional iris deficiencies, aphakia, or cataract,2 with some 
postoperative complications such as hyphema, inflammation, 
or IOP increase.
Endothelial cell loss following phakic intraocular lenses 
(IOL) is well established. The majority of anterior chamber 
phakic IOL studies rate cell loss at 3 months and 1 year 
at about 7%.3 Some mechanisms have been suggested to 
explain the endothelial cell loss: first, the surgery sacrifices 
a certain amount of endothelial cells (between 2.1% and 
7.6%), depending largely on the surgeon’s experience and is 
generally accepted as inevitable;4 second, the consequence 
of intermittent contact between the cornea and the IOL;4 and 
third, the natural age-related endothelial loss (0.6% per year).5 
An inflammatory mechanism for endothelial cell deprivation 
is also thought to play a part.6 In this case we propose that at 
least two mechanisms were involved in the rapid endothelial 
cell loss. The first one is the surgery. The NewIris is implanted 
into the anterior chamber under topical anesthesia. The 
anterior chamber is filled with viscoelastic and the folded 
implant is then inserted through a 3.2-mm corneal incision 
and unfolded. The second is the contact between the lens and 
the endothelium and between the lens and the anterior part 
of the iris, as has been shown by OCT images.
Figure 1 A) Anterior chamber image. The NewIris lens is positioned over the 
whole surface of the iris. Corneal incision to insert the lens is at twelve o’clock with 
a size of 2.8 mm; B) Iris lens diaphragm after explantation.
Figure 2 endothelial cell count. The polymorphism and polymegathism are very 
evident in both eyes, especially the left one.
Figure 3 Anterior chamber optical coherence tomography. The lens is positioned 
over the iris and is in contact with all the 360° coneoescleral trabecular meshwork.Clinical Ophthalmology
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It is well known that when an angle-supported anterior 
chamber IOL is implanted, between 7% and 21% of patients 
develop high IOP and require treatment.5 The IOP increases 
because of two mechanisms. The first one is the pupillary block 
due to lens implantation without iridotomies being performed.4 
The second is the pigment dispersion due to contact between the 
lens and the iris, which can lead to occlusion of the trabecular 
meshwork. Castanera et al7 reported some irregularities in the 
NewIris surface by scanning electron microscopy. These irregu-
larities can promote the contact between the lens and the iris, 
enhancing the pigment dispersion. In this case the hypothesis 
that pigment dispersion is the primary mechanism of elevated 
IOP is supported because there was no pupillary block and we 
saw pigment deposition in the corneal endothelium.
Data on complications associated with cosmetic iris 
implants are limited. Some authors8–11 have published pre-
vious cases with serious complications related to this lens 
as glaucoma that required trabeculectomy, corneal decom-
pensation with endothelial keratoplasty, and impairment to 
visual acuity. In this case the quick removal of the cosmetic 
iris implants avoided more serious complications but the 
endothelial cell loss was unavoidable.
The iris-lens diaphragm device is supposed to be a new 
approach to cosmetic ophthalmological surgery and in theory 
a more comfortable option than cosmetic contact lenses. As 
a result of the significant implications from this surgery, the 
authors strongly recommend not using this type of cosmetic 
implant.
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